COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente
22/09/2025
Mise à jour sur l’examen réglementaire américain du tolébrutinib dans le traitement de la sclérose en plaques secondairement progressive non récurrente Paris, le 22 septembre 2025 . La Food and Drug Administration (FDA [...]
Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
22/09/2025
Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent significantly reduced [...]
Communiqué de presse : Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP
22/09/2025
Sanofi et Regeneron voient l’autorisation du Dupixent pour le traitement de l’urticaire chronique spontanée progresser dans l’UE grâce à un avis positif du CHMP Recommandation pour les adultes et les adolescents, sur la [...]
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
22/09/2025
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over [...]
Yangtze River Pharmaceutical Group’s Innovative Anti-insomnia Drug Fazamorexant Debut at the World Sleep Congress 2025
22/09/2025
TAIZHOU, Jiangsu, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Most recently, the Phase III pivotal clinical trial results of Fazamorexant, a first-class innovative anti-insomnia drug independently developed by Yangtze River [...]
Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
21/09/2025
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-release tablets Patients reported high satisfaction [...]
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
21/09/2025
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was [...]
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
20/09/2025
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple [...]

Pages